Monthly Communication Report

Organization:	Innovative Medicines Canada/Médicaments novateurs Canada
Associated registration:	957857-371-128
Communication date:	2025-10-21
Posted date:	2025-11-13

Designated Public Office Holders who participated in the communication:	Mackenzy Metcalfe, Policy Advisor Office of the Minister of Finance, Finance Canada (FIN)
List of Details Subject matter Detail Health, Intellectual Property, International Trade, Research and Development, Science and Technology Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Free trade agreements as they relate to the biopharmaceutical industry Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Health, Research and Development, Science and Technology Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Economic Development, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, National Security/Security, Research and Development, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Communication Report amended on:	2025-11-13 previous entry: 371-654902
Reason for amendment:	The last name for Mackenzy was corrected to Mackenzy Metcalfe.
Responsible Officer who filed this communication report:	Bettina Hamelin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.